Skip to content

Therapy-Associated Saliva and Taste Change Evaluation (TASTE) in Head & Neck Cancer Patients Undergoing Radiotherapy

Therapy-Associated Saliva and Taste Change Evaluation (TASTE) in Head & Neck Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06444776
Acronym
TASTE
Enrollment
150
Registered
2024-06-06
Start date
2022-12-19
Completion date
2027-12-31
Last updated
2024-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Keywords

Head and Neck Cancer, Radiotherapy, Taste impairment, Dysgeusia, Xerostomia, Saliva, Quality of life

Brief summary

One of the main side effects of radiation therapy to the head and neck region is altered taste sensation. This causes significant morbidity and has profound effects on the quality of life (QoL) of patients. While radiation-associated toxicities like xerostomia and dysphagia are part of large investigations, data on taste impairment is sparse. The TASTE study sets out to further our understanding of this common side effect with the goal to prevent radiation-associated taste impairment in future patients. In this prospective, observational multicenter study 150 head and neck cancer patients undergoing radiation therapy will be recruited. Participants will undergo repetitive (semi-) objective and subjective assessment of their taste, smell and salivary function at specific time points before, during and after radiotherapy. Primary endpoint will be patient-reported taste impairment 12 months post radiation therapy using a standardized quality of life questionnaire (MDASI-HN). Secondary endpoints will include taste impairment measured using taste strips at 12 months and 2 years post radiation therapy. Differences between subgroups (radiation side, chemotherapy, etc.) and changes over time will be assessed while adjusting for confounding factors (e.g. age, sex, smoking history). Based on the aquired data, a normal tissue complication probability model for late radiation-associated taste impairment will be develeoped.

Interventions

DIAGNOSTIC_TESTRepetitive (semi-)objective and subjective taste, smell, and saliva analysis

Study participants will undergo repetitive assessments of their taste, smell and saliva, using quality of life questionnaires, taste strips, sniffin sticks, and analysis of salivary function and composition. Assessments will be done before treatment, in the 4th week (+/- 1 week) and last week of radiation therapy (+/- 1 week), and at 6 months (+/- 1 months) and 1 and 2 years post-therapy (+/- 3 months). At the minimum, participants are expected to complete the assessments at baseline and 1 year after the end of radiation therapy. Assessments at all other time points are strongly encouraged but will be optional.

Sponsors

Kantonsspital Aarau
CollaboratorOTHER
University of Bern
CollaboratorOTHER
University of Zurich
CollaboratorOTHER
Sonja Stieb, MD
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Head and neck cancer patients * Referred for radiation therapy with curative intent, both definitive and post-operative * Age ≥18 * Karnofsky performance index of at least 50% * Anticipated mean radiation dose to the taste bud bearing tongue mucosa or at least one of the major salivary glands (parotid, submandibular, and/or sublingual gland) of at the minimum 5 Gy

Exclusion criteria

* Pregnancy * Pre-existing subjective complete loss of taste before start of radiation therapy * Planning CT and radiation therapy with oral stent or spacer * Partial or total glossectomy which impairs taste assessments of at least one side of the tongue or impairs contouring of the taste bud bearing tongue mucosa on the planning CT * Inability to follow instructions related to study procedures or inability to fill in the questionnaires * Inability to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Taste impairment12 months post-treatmentPatient-reported taste impairment assessed by the MDASI-HN (MD Anderson Symptom Inventory Head and Neck module) questionnaire

Secondary

MeasureTime frameDescription
Taste impairment24 months post-treatmentPatient-reported taste impairment assessed by the MDASI-HN (MD Anderson Symptom Inventory Head and Neck module) questionnaire

Countries

Switzerland

Contacts

Primary ContactSonja Stieb, MD
sonja.stieb@ksa.ch+41 62 838 4179
Backup ContactOliver Riesterer, Prof., MD
oliver.riesterer@ksa.ch+41 62 838 4249

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026